Key Drivers
- Cash Conversion
- Debt Burden
- Margin Pressure
AIAI Summary
AHCO should be viewed less as a cheap defensive healthcare name and more as a risky turnaround/portfolio-cleanup story: the diabetes divestiture and capitated contract expansion could improve quality over time, but the immediate tell is deteriorating free cash flow, margin compression, and high leverage, so the stock only merits conviction if management can stabilize margins and restore positive cash conversion.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Conversion
- •Debt Burden
- •Margin Pressure
AHCO appears inexpensive on paper and still generates cash, but weak profitability, rising margin pressure, heavy leverage, and an intangible-heavy balance sheet make the equity a high-risk turnaround story.
Price Behavior
Key Price Behavior Insights:
- •Sharp breakdown
- •Lower highs/lows
- •Oversold bounce
AHCO has broken down sharply from its prior $10.2–$11.2 range over the last month, leaving the trend decisively bearish and oversold, with $5.69 as key support and $6.50–$6.71 as the first rebound hurdle.
Roughly 44% drop from the prior $10.2–$11.2 range over the last month after a hard breakdown
Sentiment & News
Key News Insights:
- •Guidance Reset
- •Margin Pressure
- •Asset Sale
AdaptHealth's Q2 earnings miss, full-year guidance cut, and goodwill impairment drove sharp share losses and legal scrutiny, even as organic revenue growth and the Diabetes Health sale show ongoing portfolio repositioning.
The news is likely negative for AHCO in the near term, as reduced profitability and heightened legal risk outweigh continued revenue growth and strategic restructuring
Similar Companies in Healthcare
Other companies in the same sector with AI ratings